Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 4Phase 3 2Phase 1 2Phase 2/3 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Plasma cell 1Myeloid 1

Conditions

Lymphoma, Non-Hodgkin 3Hematologic Neoplasms 2Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Leukemia 1Hodgkin Disease 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 143pembrolizumab 127Nivolumab 116Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 73Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Ipilimumab 55Docetaxel 54Bortezomib 54Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × Hematopoietic Stem Cell Transplantation × Clear all
NCT01350258 2025-05-31

Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

Thomas Jefferson University

Phase 1/2 Terminated
8 enrolled 8 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT03583424 2025-05-14

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Completed
19 enrolled 12 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT01458366 2025-04-30

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Thomas Jefferson University

Phase 1/2 Completed
38 enrolled 17 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT00429416 2016-11-29

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Thomas Jefferson University

Phase 1/2 Completed
14 enrolled 11 charts
Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡